Literature DB >> 12829178

Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation.

Cecile Ancey1, Emmanuelle Menet, Pierre Corbi, Sandra Fredj, Martine Garcia, Catherine Rücker-Martin, Jocelyn Bescond, Franck Morel, John Wijdenes, Jean-Claude Lecron, Daniel Potreau.   

Abstract

OBJECTIVES: Recent in vivo and in vitro studies in animals have demonstrated that cytokines of the IL-6 family are involved in cardiac hypertrophy and in protection of cardiomyocytes against apoptosis. The present study aims to analyse the capacity of human atrial cardiac cells (i.e., cardiomyocytes and fibroblasts) to display the gp130 receptor subunit, and to evaluate its functionality.
METHODS: Twenty human atrial biopsies were used for immunohistochemistry, in situ hybridisation, and western blot analysis or dissociated for isolation and primary culture of cardiac cells.
RESULTS: Fibroblasts present in tissue or maintained in primary culture clearly express gp130 whereas the signal in cardiomyocytes is weaker. Culture of cardiac cells with a gp130 agonist antibody enhances atrial natriuretic peptide (ANP), beta myosin heavy chain (beta-MHC) expression in cardiomyocytes, and significantly increases the cell surface area microm(2)). This process could involve STAT3 (signal transducer and activator of transcription 3) phosphorylation.
CONCLUSIONS: These results demonstrate that gp130 activation in human cardiac cells leads to cardiomyocyte hypertrophy. We discuss several hypotheses on the role of IL-6-type cytokines on cardiomyocyte functions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829178     DOI: 10.1016/s0008-6363(03)00346-8

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  15 in total

1.  Molecular characterization and expression analysis of the putative interleukin 6 receptor (IL-6Rα and glycoprotein-130) in rainbow trout (Oncorhynchus mykiss): salmonid IL-6Rα possesses a polymorphic N-terminal Ig domain with variable numbers of two repeats.

Authors:  Maria M Costa; Tiehui Wang; Milena M Monte; Christopher J Secombes
Journal:  Immunogenetics       Date:  2011-10-29       Impact factor: 2.846

2.  Cardioprotective stress response in the human fetal heart.

Authors:  John G Coles; Cathy Boscarino; Mark Takahashi; Diane Grant; Astra Chang; Julia Ritter; Xiaojing Dai; Changqing Du; Gabriel Musso; Hideaki Yamabi; Jason Goncalves; Ashu Sunny Kumar; James Woodgett; Huanzhang Lu; Gregory Hannigan
Journal:  J Thorac Cardiovasc Surg       Date:  2005-05       Impact factor: 5.209

3.  Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats.

Authors:  Giselle C Meléndez; Jennifer L McLarty; Scott P Levick; Yan Du; Joseph S Janicki; Gregory L Brower
Journal:  Hypertension       Date:  2010-07-06       Impact factor: 10.190

4.  IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart.

Authors:  Indroneal Banerjee; John W Fuseler; Arti R Intwala; Troy A Baudino
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-20       Impact factor: 4.733

5.  Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody.

Authors:  Junya Kanda; Hiroshi Kawabata; Yuhei Yamaji; Tatsuo Ichinohe; Takayuki Ishikawa; Toshihiro Tamura; Yutaka Furukawa; Takeshi Kimura; Toru Kita; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

Review 6.  JAK redux: a second look at the regulation and role of JAKs in the heart.

Authors:  Mazen Kurdi; George W Booz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

Review 7.  Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects.

Authors:  P Fischer; D Hilfiker-Kleiner
Journal:  Br J Pharmacol       Date:  2008-02-04       Impact factor: 8.739

8.  Red cell distribution width and inappropriateness of left ventricular mass in patients with untreated essential hypertension.

Authors:  Lizhang Chen; Zhanzhan Li; Yanyan Li; Jing Xue; Peng Chen; Shipeng Yan; Caixiao Jiang; Yingyun Hu; Xing Qiao
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

9.  Cardiomyocytes in Young Infants With Congenital Heart Disease: a Three-Month Window of Proliferation.

Authors:  Lincai Ye; Lisheng Qiu; Haibo Zhang; Huiwen Chen; Chuan Jiang; Haifa Hong; Jinfen Liu
Journal:  Sci Rep       Date:  2016-03-15       Impact factor: 4.379

10.  Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo.

Authors:  Barbara Coles; Ceri A Fielding; Stefan Rose-John; Jürgen Scheller; Simon A Jones; Valerie B O'Donnell
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.